MR imaging of the small bowel with increasing concentrations of an oral osmotic agent

Area of Science:

• Medical Imaging
• Radiology
• Gastroenterology

Background:

• Gastrografin is an oral contrast agent used in MR imaging.
• Its use may be associated with adverse effects.
• Optimizing its concentration is crucial for balancing diagnostic quality and patient comfort.

Purpose of the Study:

• To evaluate the impact of increasing Gastrografin concentrations on MR imaging quality.
• To assess the relationship between Gastrografin concentration and the incidence/severity of adverse effects.

Main Methods:

• Prospective study with 24 healthy volunteers randomized into four Gastrografin concentration groups (0%, 10%, 25%, 50%).
• Bowel image quality assessed by three radiologists based on distension, homogeneity, and wall delineation.
• Adverse events scored by subjects on a 1-5 scale.

Main Results:

• Improved bowel distension and MR image quality correlated with higher Gastrografin concentrations.
• Significant dose-response relationship observed between increasing osmolality and bowel diameter/adverse event scores.
• Most frequent adverse reactions included diarrhea, nausea, and poor palatability.

Conclusions:

• Increasing Gastrografin concentration enhances MR imaging quality but also increases adverse effects.
• A gradient exists between osmolality, image quality, and adverse event severity.
• The optimal Gastrografin concentration depends on individual patient tolerance to side effects.